{"bill": {"#text": " \n", "form": {"current-chamber": {"#tail": " \n", "@display": "yes", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n", "congress": {"#tail": " ", "@display": "yes", "#text": "113th CONGRESS"}, "#tail": " \n", "legis-num": {"#tail": "\n", "#text": "H. R. 4299"}, "official-title": {"#tail": " \n", "#text": "To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.", "@display": "yes", "pagebreak": {"#tail": "\n    "}}, "session": {"#tail": " \n", "@display": "yes", "#text": "2d Session"}, "distribution-code": {"#tail": " \n", "@display": "yes", "#text": "IB"}, "action": [{"action-date": {"#tail": " \n", "@date": "20140326", "#text": "March 26, 2014"}, "#tail": " \n", "action-desc": {"#tail": " \n", "#text": "\n        ", "committee-name": [{"#tail": ", and in addition to the ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, {"@deleted-display-style": "strikethrough", "#tail": ", for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned", "@committee-id": "HJU00", "@added-display-style": "italic", "#text": "Committee on the Judiciary"}], "sponsor": {"#tail": " (for himself and ", "#text": "Mr. Pitts", "@name-id": "P000373"}, "cosponsor": {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Pallone", "@name-id": "P000034"}}, "#text": " \n"}, {"action-date": {"#tail": "\n", "@date": "20140729", "#text": "July 29, 2014"}, "#tail": "\n", "action-desc": {"#tail": "\n", "#text": "Reported from the ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}}, "#text": "\n"}, {"action-date": {"#tail": "\n", "@date": "20140729", "#text": "July 29, 2014"}, "#tail": "\n", "action-desc": {"#tail": "\n", "#text": "Referral to the ", "committee-name": {"@deleted-display-style": "strikethrough", "#tail": " extended for a period ending not later than September 19, 2014", "@committee-id": "HJU00", "@added-display-style": "italic", "#text": "Committee on the Judiciary"}}, "#text": "\n"}, {"action-date": {"#tail": "\n", "@date": "20140919", "#text": "September 19, 2014"}, "#tail": "\n", "action-desc": {"#tail": "\n", "#text": "Additional sponsors: ", "cosponsor": [{"#tail": ", ", "#text": "Mr. Burgess", "@name-id": "B001248"}, {"#tail": ", ", "#text": "Mrs. McMorris Rodgers", "@name-id": "M001159"}, {"#tail": ", ", "#text": "Mrs. Blackburn", "@name-id": "B001243"}, {"#tail": ", ", "#text": "Mr. Gingrey of Georgia", "@name-id": "G000550"}, {"#tail": ", ", "#text": "Mr. Griffith of Virginia", "@name-id": "G000568"}, {"#tail": ", ", "#text": "Mr. Gene Green of Texas", "@name-id": "G000410"}, {"#tail": ", ", "#text": "Mr. Latta", "@name-id": "L000566"}, {"#tail": ", ", "#text": "Mr. Engel", "@name-id": "E000179"}, {"#tail": ", ", "#text": "Ms. Shea-Porter", "@name-id": "S001170"}, {"#tail": ", ", "#text": "Mr. Butterfield", "@name-id": "B001251"}, {"#tail": ", ", "#text": "Mr. Tonko", "@name-id": "T000469"}, {"#tail": ", ", "#text": "Mr. Johnson of Ohio", "@name-id": "J000292"}, {"#tail": ", and ", "#text": "Mr. Harper", "@name-id": "H001045"}, {"#tail": "\n      ", "#text": "Mr. Collins of Georgia", "@name-id": "C001093"}]}, "#text": "\n"}, {"#tail": "\n", "#text": "\n", "action-desc": {"#tail": "\n", "#text": "\n        ", "pagebreak": {"#tail": "\n      "}}}, {"action-date": {"#tail": "\n", "@date": "20140919", "#text": "September 19, 2014"}, "#tail": " \n", "action-desc": {"#tail": "\n", "#text": "Reported from the ", "committee-name": {"@deleted-display-style": "strikethrough", "#tail": " with an amendment", "@committee-id": "HJU00", "@added-display-style": "italic", "#text": "Committee on the Judiciary"}}, "#text": "\n", "action-instruction": [{"#tail": "\n", "#text": "Strike out all after the enacting clause and insert the part printed in italic"}, {"#tail": "\n", "#text": "For text of introduced bill, see copy of bill as introduced on March 26, 2014"}]}], "associated-doc": {"#tail": " \n", "@display": "yes", "#text": "[Report No. 113\u2013565, Parts I and II]", "@role": "report"}, "calendar": {"#tail": "\n", "@display": "yes", "#text": "Union Calendar No. 451"}, "legis-type": {"#tail": " \n", "#text": "A BILL"}}, "@bill-stage": "Reported-in-House", "@bill-type": "olc", "endorsement": {"action-date": {"#tail": "\n", "@date": "20140919", "#text": "September 19, 2014"}, "#tail": "\n", "@display": "yes", "action-desc": {"#tail": "\n  ", "#text": "Reported from the ", "committee-name": {"@deleted-display-style": "strikethrough", "#tail": " with an amendment", "@committee-id": "HJU00", "@added-display-style": "italic", "#text": "Committee on the Judiciary"}}, "#text": "\n"}, "@dms-id": "H4C41E6F7E04B47078D23FC4CA2D6C3A0", "@public-private": "public", "legis-body": {"@style": "OLC", "@committee-id": "HJU00", "@changed": "added", "#tail": " \n", "section": [{"@section-type": "section-one", "#tail": "\n", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Improving Regulatory Transparency for New Medical Therapies Act", "@value": "Improving Regulatory Transparency for New Medical Therapies Act", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "HC2A3AC213A2248C39D6657608AE29CC7"}, {"#tail": "\n", "text": {"#tail": "\n    ", "quote": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " under this subsection to control a drug or other substance not previously scheduled, where the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " has recommended the drug or other substance be placed in schedule II, III, IV, or V, shall be commenced not later than 120 days after receipt of written recommendations from the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ". The final rule shall be issued not later than 60 days after the date on which both the public comment period has closed and the drug or other substance is the subject of an approved new drug application under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", unless a hearing on the proposed rule is granted by the ", "@entity-type": "act", "#text": "section 505 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "Any such proceedings initiated at the request of the "}, "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following: ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 201(a) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:201/ss:a"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 811(a)", "@value": "usc/21/811/a"}, "@parsable-cite": "usc/21/811", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Scheduling of substances included in new FDA-approved drugs"}, "#text": "\n      ", "@id": "H4127A3FACFC84D5E84B56D6144D8AEF7"}, {"#tail": "\n", "text": {"#tail": "\n", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 303 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 823", "@value": "usc/21/823"}, "@parsable-cite": "usc/21/823", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Enhancing new drug development"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "subsection": {"#tail": "\n        ", "#text": "\n          ", "enum": {"#tail": "\n", "#text": "(i)"}, "@id": "H7206BE5381174E06BA822F88D85B2A6C", "paragraph": [{"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall register an applicant or serve an order to show cause upon an applicant pursuant to ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " not later than 180 days after receipt of an application and all information the ", "@entity-type": "act", "#text": "section 304(c) of this Act", "@value": "Controlled Substances Act/s:304/ss:c"}, {"#tail": " deems necessary to make a determination under subsection (d).", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "For the purposes of registration to manufacture a controlled substance under subsection (d) of this section for use only in a clinical trial, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@display-inline": "yes-display-inline", "#text": "\n            ", "@id": "H2E48F28F7A0445479C6C7C8E1C7BF1ED"}, {"@indent": "up1", "#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall, in accordance with regulations issued by the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ", issue a notice of application not later than 90 days after receipt of an application and all information the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " deems necessary to issue a notice of application. Following the close of the comment period and receipt of all information the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " deems necessary to make a determination under subsection (a), the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " shall register an applicant or serve an order to show cause upon an applicant pursuant to ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " within 180 days, unless a hearing on the application has been granted by the ", "@entity-type": "act", "#text": "section 304(c) of this Act", "@value": "Controlled Substances Act/s:304/ss:c"}, {"#tail": " pursuant to ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ". ", "@entity-type": "act", "#text": "section 1008(i) of the Controlled Substances Import and Export Act", "@value": "Controlled Substances Import and Export Act/s:1008/ss:i"}], "#text": "For the purposes of registration to manufacture a controlled substance under subsection (a) for use only in a clinical trial, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "#text": "\n            ", "@id": "H1A37C68375EB466496CB394DF5F49C5D"}]}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H9FF6669FF37A45F19056E0B88F2053B7"}, "#text": "\n      ", "@id": "HDCEA83F5C5EA456FAD6295205940E18D"}], "@display-enacting-clause": "yes-display-enacting-clause", "@reported-display-style": "italic", "#text": "\n", "@id": "HE5D5B25E65E745DDB000E4216837D481"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-09-19"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 4299 RH: Improving Regulatory Transparency for New Medical Therapies Act"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}